Deltex Medical Group plc Revenues Up, Margin increased, Cash costs reduced

Deltex Medical Group PLC

Deltex Medical Group plc (LON:DEMG), the global leader in oesophageal Doppler monitoring (“ODM”) today announced its results for the six-month period ended 30 June 2017.

Statutory results

· Revenue up 7% to £2.9m (H1 2016: £2.7m)

· Gross margin increased to 76% (H1 2016: 64%)

· Operating cash costs reduced by £0.3m to £2.9m (H1 2016: £3.2m)

· Cash operating loss reduced by 57% to £0.6m (H1 2016: £1.4m):

· Net cash used in operating activities was £0.4m, £1.1m (73%) lower than in H1 2016 (£1.5m)

· Cash available of £0.2m (31 December 2016, £0.6m) with £0.5m additional capital raised in July

Key performance measures (vs. H1 2016)

· US probe revenues up £0.2m, 21%, at £1.0m

· Total US revenues up £0.3m, 35% (20% local currency), at £1.2m

o Target of 30th platform account achieved

o Two further large hospitals added since with additional accounts pending

· International probe and total revenues down £0.1m (9%) due to timing differences on distributor orders: satisfactory progress with end user sales

· UK probe revenues at £0.7m down 12% with total UK revenues at £1.0m down 3%

Operating Highlights

· US sales development continues progress

· Margin improvement following manufacturing process changes

· Veterinary system introduced in H1 for launch in H2

· High Definition – Impedance Cardiography (HD – ICG) added to CardioQ-ODM+ platform in H1: full launch into export markets in H2 subject to regulatory approvals

· Unique offer to customers from combining the three leading advanced haemodynamic technologies on a single monitoring platform

· Additional new product releases in the pipeline

Nigel Keen, Deltex Medical Group Plc Chairman, commented: “In the first half of 2017, Deltex Medical increased its sales, improved its margins and reduced its costs. We are therefore substantially on course to reach our key short-term objective of moving through the operating cash break-even point.

“The Company entered the traditionally stronger second half with sales traction in its US and International businesses, a difficult but improved UK trend and the prospect of incremental returns from investments made in product development. The move from a single to a multiple technology platform increases significantly the Company’s marketing, commercial and strategic options.”

There will be an Investor Event this evening, 11 September, at El Vino Masons Avenue, 12-14 Masons Avenue London, EC2V 5BT from 18:00 and will take the form of a Company presentation followed by a Q&A session.

Investors and shareholders who wish to attend the event should register their interest here:

https://www.eventbrite.co.uk/e/deltex-investor-event-tickets-37415825742

There will be a management webinar for investors on 12 September 2017 at 12.45pm. If you would like to join the webinar, please register here:

https://www.equitydevelopment.co.uk/2017/08/30/deltex-medical-webinar-tuesday-12th-september-1245pm/

The presentations from both events will also be made available on the Company’s website.

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index